相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach
Asim Azhar et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)
Mucormycosis with orbital compartment syndrome in a patient with COVID-19
Amanda Werthman-Ehrenreich
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Stephen R. Brand et al.
CLINICAL INFECTIOUS DISEASES (2021)
Mucormycosis: time to address this deadly fungal infection
Neil Stone et al.
LANCET MICROBE (2021)
Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study
Alejandro Rodriguez-Molinero et al.
MEDICINA CLINICA (2021)
A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis
Daniela Pasero et al.
INFECTION (2021)
Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens
Katharina Rosam et al.
JOURNAL OF FUNGI (2021)
Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance
Surbhi Khurana et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2021)
Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum
S. Sharma et al.
JOURNAL OF LARYNGOLOGY AND OTOLOGY (2021)
Isolated pulmonary mucormycosis in an immunocompetent patient: a case report and systematic review of the literature
Jianhan He et al.
BMC Pulmonary Medicine (2021)
COVID-19 Associated Mucormycosis: A Systematic Review from Diagnostic Challenges to Management
Farah Yasmin et al.
DISEASES (2021)
Sino-orbital mucormycosis in a COVID-19 patient: A case report
Aastha Maini et al.
INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS (2021)
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
Mili Kapoor et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
New azole antifungals with a fused triazinone scaffold
David Montoir et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Antifungal effects of statins
Alireza Tavakkoli et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
Teclegiorgis Gebremariam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Synthetic Approaches to New Drugs Approved during 2018
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Co-infection with respiratory pathogens among COVID-2019 cases
Xiaojuan Zhu et al.
VIRUS RESEARCH (2020)
Epidemiology and Diagnosis of Mucormycosis: An Update
Anna Skiada et al.
JOURNAL OF FUNGI (2020)
Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in COVID-19 Patient: A Case Report
Epifanio Silvino do Monte Junior et al.
CLINICAL ENDOSCOPY (2020)
Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran
Mohammadreza Salehi et al.
MYCOPATHOLOGIA (2020)
In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
Olga Rivero-Menendez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts
Steven T. Denham et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles
Lysett Wagner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis
Teclegiorgis Gebremariam et al.
SCIENCE ADVANCES (2019)
CRISPR-Cas9-mediated disruption of the HMG-CoA reductase genes of Mucor circinelloides and subcellular localization of the encoded enzymes
Gabor Nagy et al.
FUNGAL GENETICS AND BIOLOGY (2019)
The antiviral Sofosbuvir against mucormycosis: an in silico perspective
Abdo A. Elfiky
FUTURE VIROLOGY (2019)
Epidemiology and clinical characteristics of invasive mould infections: A multicenter, retrospective analysis in five Asian countries
P. Rotjanapan et al.
MEDICAL MYCOLOGY (2018)
In Vitro and In Vivo Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on Aspergillus fumigatus Infection
Thomas Colley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
New spiro-oxindole constructed with pyrrolidine/thioxothiazolidin-4-one derivatives: Regioselective synthesis, X-ray crystal structures, Hirshfeld surface analysis, DFT, docking and antimicrobial studies
Assem Barakat et al.
JOURNAL OF MOLECULAR STRUCTURE (2018)
Challenges in the diagnosis and treatment of mucormycosis
A. Skiada et al.
MEDICAL MYCOLOGY (2018)
Recent advances in the molecular diagnosis of mucormycosis
Sanjeet S. Dadwal et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Overexpression or Deletion of Ergosterol Biosynthesis Genes Alters Doubling Time, Response to Stress Agents, and Drug Susceptibility in Saccharomyces cerevisiae
Somanon Bhattacharya et al.
MBIO (2018)
Facial Regioselective Synthesis of Novel Bioactive Spiropyrrolidine/Pyrrolizine-Oxindole Derivatives via a Three Components Reaction as Potential Antimicrobial Agents
Huwaida M. E. Hassaneen et al.
MOLECULES (2017)
Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae
Anne-Pauline Bellanger et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
The Mechanistic Targets of Antifungal Agents: An Overview
Tryphon K. Mazu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis?
Anuradha Chowdhary et al.
PLOS PATHOGENS (2016)
Isavuconazole as salvage therapy for mucormycosis
Bianca Graves et al.
MEDICAL MYCOLOGY CASE REPORTS (2016)
Etest Cannot Be Recommended for In Vitro Susceptibility Testing of Mucorales
Rita Caramalho et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae
Anne-Pauline Bellanger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection
Teclegiorgis Gebremariam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates
Frederic Lamoth et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Black Molds and Melanized Yeasts Pathogenic to Humans
Anuradha Chowdhary et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)
Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review
Hector Eloy Tamez-Perez et al.
WORLD JOURNAL OF DIABETES (2015)
Isavuconazole Therapy Protects Immunosuppressed Mice from Mucormycosis
Guanpingsheng Luo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme
A. G. S. Warrilow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis
Russell E. Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments
Daniel Michal Kaminski
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS (2014)
Successful isavuconazole salvage therapy in a patient with invasive mucormycosis
J. Ervens et al.
INFECTION (2014)
Isavuconazole Treatment of a Patient with Disseminated Mucormycosis
Driele Peixoto et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2014)
Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India
Anuradha Chowdhary et al.
MYCOSES (2014)
Amphotericin forms an extramembranous and fungicidal sterol sponge
Thomas M. Anderson et al.
NATURE CHEMICAL BIOLOGY (2014)
Drug Combinations against Mucor irregularis In Vitro
Shuzhen Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Combination Therapy for Mucormycosis: Why, What, and How?
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2012)
Rapamycin Exerts Antifungal Activity In Vitro and In Vivo against Mucor circinelloides via FKBP12-Dependent Inhibition of Tor
Robert J. Bastidas et al.
EUKARYOTIC CELL (2012)
Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales
Roxana G. Vitale et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Amphotericin primarily kills yeast by simply binding ergosterol
Kaitlyn C. Gray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Hidden Killers: Human Fungal Infections
Gordon D. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Rhino-Orbital-Cerebral Mucormycosis
Maria N. Gamaletsou et al.
CURRENT INFECTIOUS DISEASE REPORTS (2012)
Efficacy of Caspofungin in Neutropenic and Corticosteroid-Immunosuppressed Murine Models of Invasive Pulmonary Mucormycosis
Russell E. Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods
Michael A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
Katsura Hata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities
Daniel S. Palacios et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
ANTIFUNGAL ACTIVITY OF STATINS AND THEIR INTERACTION WITH AMPHOTERICIN B AGAINST CLINICALLY IMPORTANT ZYGOMYCETES
L. Galgoczy et al.
ACTA BIOLOGICA HUNGARICA (2010)
Antifungal Activity of Colistin against Mucorales Species In Vitro and in a Murine Model of Rhizopus oryzae Pulmonary Infection
Ronen Ben-Ami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi
Ildiko Nyilasi et al.
FEMS MICROBIOLOGY LETTERS (2010)
Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation
Sylvie Callegari et al.
FEMS YEAST RESEARCH (2010)
In vitro interactions between primycin and different statins in their effects against some clinically important fungi
Ildiko Nyilasi et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2010)
Cloning of the Rhizomucor miehei 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene and its heterologous expression in Mucor circinelloides
Gyoengyi Lukacs et al.
ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY (2009)
Are Statins Applicable for the Prevention and Treatment of Zygomycosis?
Laszlo Galgoczy et al.
CLINICAL INFECTIOUS DISEASES (2009)
Genomic Analysis of the Basal Lineage Fungus Rhizopus oryzae Reveals a Whole-Genome Duplication
Li-Jun Ma et al.
PLOS GENETICS (2009)
Combination echinocandin-polyene treatment of murine mucormycosis
Ashraf S. Ibrahim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Biological consequences of statins in Candida species and possible implications for human health
K. Wikhe et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes
Laszlo Galgoczy et al.
FEMS MICROBIOLOGY LETTERS (2007)
The weapon potential of human pathogenic fungi
Arturo Casadevall et al.
MEDICAL MYCOLOGY (2006)
Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole
G Chamilos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient:: Recovery after posaconazole therapy (vol 80, pg 544, 2005)
O Brugière et al.
TRANSPLANTATION (2005)
Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: Recovery after posaconazole therapy
B Dupont
TRANSPLANTATION (2005)
Novel perspectives on mucormycosis: Pathophysiology, presentation, and management
B Spellberg et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice
B Spellberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient
D Quinio et al.
MEDICAL MYCOLOGY (2004)
Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment:: more evidence of the utility of azoles for zygomycosis
DP Eisen et al.
MYCOSES (2004)
Zygomycosis in neutropenic patients with past Aspergillus infection:: a role for posaconazole?
L Ide et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Activity of posaconazole in treatment of experimental disseminated zygomycosis
E Dannaoui et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Cyclophilin D as a drug target
PC Waldmeier et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly
K Tsukahara et al.
MOLECULAR MICROBIOLOGY (2003)
In vitro susceptibilities of zygomycetes to conventional and new antifungals
E Dannaoui et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model
QN Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes
QN Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi:: Report from SENTRY Antimicrobial Surveillance Program, 2000
MA Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
分享论文
